Table 2.
Parameter estimates for cardiac biomarker models anthracycline-troponin T and trastuzumab-LVEF
| Parameter | Unit | Parameter estimate | RSE (%) | Shrinkage (%) |
|---|---|---|---|---|
| Anthracycline—troponin T model | ||||
| Troponin T baseline (TRP0) | ng/L | 4.72 | 3.5 | – |
| Elimination rate constant K-PD model (ke) | Day−1 | 8.49 × 10−3 | 4.0 | – |
| Proportional effect (anthracyclines-troponin T) (SLOPE) | ng−1 L | 8.84 × 10−3 | 7.0 | – |
| Proportional anthracycline-type effect on SLOPE | 0.524 | 17.5 | – | |
| Between-subject variability (%) | ||||
| Slope effect on TRP0 (SLOPE) | CV | 57.7 | 23.3 | 31.0 |
| Troponin T baseline (TRP0) | CV | 39.2 | 9.9 | 12.6 |
| Residual variability | ||||
| Proportional residual error troponin T | % | 30.1 | 4.2 | 11.2 |
| Trastuzumab—LVEF model | – | |||
| LVEF baseline value (LVEF0) | 0.599 | 0.6 | – | |
| Recovery half-life (T1/2rec) | Day | 67.9 | 17.2 | – |
| Sensitivity to LVEF decline (EC50) | mg/L | 2.18 × 105 | 23.4 | – |
| Maximum troponin T effect on EC50 | − 1.16 | 23.4 | – | |
| Between-subject variability (%) | ||||
| LVEF baseline value (LVEF0) | CV | 7.07 | 16.7 | 9.9 |
| Sensitivity to LVEF decline (EC50) | CV | 82.9 | 43.1 | 26.0 |
| Correlation a | – | 0.585 | ||
| Residual variability | ||||
| Proportional residual error LVEF | % | 7.8 | 2.9 | 8.3 |
CV coefficient of variation, SD standard deviation, RSE relative standard error
aCorrelation derived from the variance–covariance matrix of the random effects